BINAH CAPITAL GROUP INC
BCGNASDAQTrading Snapshot
- Day Range
- $1.55 – $1.70
- 52-Week Range
- $0.95 – $3.44
- Volume (shares)
- 224,013
- Avg Volume (shares)
- —
- Shares Outstanding
- 17.1M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- $182M
- Last Q Revenue
- $51M
- P/E Ratio
- 7.4
- P/S Ratio
- 0.2x
- EPS (TTM)
- $0.25
- Dividend Yield
- 4.06%
- Dilution (1yr)
- +1.3%
BINAH CAPITAL GROUP INC
BCGAbout BINAH CAPITAL GROUP INC
Binah Capital Group, Inc. (BCG), along with its associated companies, is active in the wealth management sector. The firm furnishes financial advisors with comprehensive execution capabilities for a broad spectrum of investments, including equities, fixed-income securities, exchange-traded funds (ETFs), and options. Furthermore, it supplies essential support services to these advisors, encompassing research, regulatory compliance, supervisory guidance, and accounting. BCG's product portfolio also features mutual funds and various insurance solutions, in addition to specialized alternative investments like non-traded real estate investment trusts (REITs), unit trusts, and both fixed and variable annuities. Established in 2016, Binah Capital Group maintains its corporate headquarters in Albany, New York, and operates as a subsidiary of MHC Securities, LLC.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Binah Capital Group Reports Results for Third Quarter of 2026
- Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion -

enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for